Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...
Verywell Health on MSN2d
Spravato Nasal Spray Can Now Be Used Alone for Treatment-Resistant DepressionPeople with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...
The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
The U.S. Food and Drug Administration recently expanded approval of the nasal spray SPRAVATO, a ketamine-derived drug, as a treatment for depression. A clinic in Denver is looking to help those ...
A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The ...
(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...
The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback